COMPANY PROFILE / NANOTECHNOLOGY
Genevant Sciences
A privately held Roivant subsidiary that lets other companies use its LNP and GalNAc-conjugate delivery technology
Genevant Sciences is a privately held company that licenses nucleic acid delivery technology (lipid nanoparticles [LNPs] and GalNAc conjugates) to pharmaceutical and biotechnology companies. It was set up in April 2018 by Roivant Sciences and Arbutus Biopharma; Roivant holds 83% and Arbutus about 16% (basic common shares, 31 March 2026). It is not a company selling its own drugs: it licenses technology to Editas Medicine, Epitopea, Repair Biotechnologies, Novo Nordisk and others and takes upfront payments, milestones and royalties. It has also, with Arbutus and on patents licensed from Arbutus, pursued patent suits against Moderna and Pfizer/BioNTech. Under the March 2026 settlement with Moderna, its share of $771.6 million was paid on 8 July 2026.
Because Genevant is not listed, its own revenue, profit and headcount are not published. This article sorts out what could and could not be confirmed from the filings of its parent Roivant, Arbutus's disclosures, the company's website and press releases, and court documents. Patent litigation is treated neutrally, as each party's position; this article does not judge whether any patent is valid or infringed.
- At a glance: Genevant and its place in nanotechnology
- Logo and naming
- Where the company sits in nanotechnology
- Company scale
- Resources committed to nanotechnology
- Track record
- Plans
- What the company is aiming for in nanotechnology
- Partnership map for nanotechnology
- Technologies, products and services
- Risks
- Glossary
- References
- Claim-to-source audit
1. At a glance: Genevant and its place in nanotechnology
Cambridge (USA)
Basel (Switzerland)From "Our locations" on the website; headcount per site is not disclosed
Roivant 83%64% fully diluted. Arbutus holds about 16% (31 March 2026)
(LNP technology provider)Does not sell drugs of its own; licenses delivery technology
conjugate deliveryTwo platforms: LNP for mRNA and gene editors, and ligand conjugates for siRNA (company's description)
+ 28 licensed from ArbutusAbout 758 issued and pending in total (our calculation), as of 6 April 2026 (Roivant's 10-K)
Genevant is not a company selling LNP drugs; it is a company that lets others use LNP and GalNAc-conjugate technology Sourced. Roivant's 10-K describes it as "a technology-focused nucleic acid delivery and development company ... currently focused on partnering with other pharmaceutical or biotechnology companies." Its income comes from upfront payments, R&D reimbursement, milestones, royalties and profit sharing, and from patent licenses and litigation settlements.
The core patents are exclusively licensed from Arbutus (outside hepatitis B and certain other fields). Sublicensing and litigation income that Genevant receives is shared with Arbutus under contract: for example, the Moderna up-front payment was split 80% to Genevant and 20% to Arbutus after litigation costs Sourced. Reading either company's income means reading the two separately.
2. Logo and naming
The logo is the corporate logo published in the header of the company's official website (genevant.com), the word GENEVANT with a helix mark, taken as it is. It has not been recreated with generated images.
Naming: "Genevant" is used for several legal entities. Roivant's 10-K distinguishes the parent Genevant Sciences Ltd. (GSL) from its subsidiary Genevant Sciences GmbH (GSG, Basel), which is the party to contracts, patents and lawsuits. The website also lists a US entity, Genevant Sciences, Inc. (Cambridge), and a Canadian site (Vancouver). Arbutus's 10-K calls them collectively "Genevant."
Official site: https://www.genevant.com/3. Where the company sits in nanotechnology
Genevant's main type is nanomedicine, with no secondary type. It does not develop and sell medicines itself but provides delivery technology and patents. The table sorts out which materials, processes and uses are central, as far as the company's own materials confirm.
| Material / use | Role at Genevant | Primary sources found | Type |
|---|---|---|---|
| LNP delivery technology (for mRNA and gene editors) | Central. The company says it supports vaccines, therapeutic proteins, in vivo CAR-T and gene editing, and is extending delivery beyond the liver (T cells, hematopoietic stem and progenitor cells, lung, hepatic stellate cells) | Website, Roivant's 10-K | Sourced (company's description) |
| Ligand conjugates (GalNAc and others) | Second pillar. siRNA carrying sugars such as GalNAc to reach liver cells and others. A next-generation structure aims to improve endosomal release (the company says about an order of magnitude more potent than a standard GalNAc conjugate in non-human primates). Arbutus's imdusiran provides clinical validation (Roivant) | Website, Roivant's 10-K | Sourced (company's description) |
| Patents and license management | Central. Own 29 families plus 28 licensed from Arbutus; sublicensing and infringement suits are sources of income | Roivant's 10-K and 10-Q | Sourced |
| Own manufacturing plant | Not found. The website says its process has been scaled to batches of up to a kilogram of nucleic acid, but does not say where or by whom it is made | ― | Not yet confirmed |
4. Company scale
Genevant is not listed, and its own revenue, profit and employee count are not published. What can be confirmed is the part of Roivant's consolidated figures that relates to Genevant, plus ownership and patent counts.
| Item | Content |
|---|---|
| Ownership (31 March 2026) | Roivant 83% (64% fully diluted), Arbutus about 16%. Under the shareholders agreement Roivant has substantial control of Genevant, and Arbutus may send a non-voting observer to board meetings |
| Roivant consolidated revenue (March year-end) | $8.26 million (FY to March 2026), $29.05 million (FY2025) and $32.71 million (FY2024), "primarily driven by amounts earned in connection with license agreements at Genevant," per Roivant. Genevant's own figure is not disclosed |
| Settlement booked (Roivant) | Booked a $770.2 million "gain on litigation settlement" for Genevant's share in the year to March 2026. Actual receipt on 8 July 2026 was $771.6 million (adjusted for final litigation costs) |
| Patents (6 April 2026) | Owned or co-owned: 29 families, 45 issued, 118 pending (expiring 2029-2045). Licensed from Arbutus: 28 families, 485 issued, 110 pending (expiring June 2025-2041). Total 45 + 118 + 485 + 110 = 758 Our calculation |
| Management | CEO James Heyes and Executive Chair Pete Lutwyche (both since March 2025), both formerly at Arbutus (website biographies) |
Roivant booked $22.9 million of employee bonuses related to the settlement at end-June 2026 and says Genevant's parent expects to distribute up to $188 million to common shareholders other than Roivant (including Arbutus) and to holders of equity awards Sourced. How much of the $771.6 million remains in Genevant depends on that distribution and on future litigation costs; the remainder is not published Not yet confirmed.
5. Resources committed to nanotechnology
The table sorts out, for people, money, outside ties and universities, what was and was not confirmed.
| Item | What was confirmed | Type |
|---|---|---|
| People (R&D sites and headcount) | Sites are Vancouver, Cambridge and Basel. R&D headcount is not disclosed. The website cites "500+ novel, in-house lipid compounds," over 20 years of LNP experience and experts in lipid chemistry, formulation, pharmacology and scale-up. Management is largely from Arbutus | Sourced (company's description) / not disclosed |
| Money (R&D spending and capex) | Not disclosed. The amounts that can be confirmed are the settlement share ($771.6 million), the distribution from it (up to $188 million) and the bonus accrual ($22.9 million) | Not disclosed |
| Equity, acquisitions, JVs and divestments | Set up in April 2018 by Roivant and Arbutus. In July 2020 Roivant recapitalized it by an equity investment and conversion of convertible debt, and Arbutus invested $2.5 million. No investment in or acquisition of other companies by Genevant was found | Sourced / not found (investments or acquisitions by Genevant) |
| Universities, institutes and public funds | Not found. The website has a Publications page, but the materials read for this article describe no joint research with a particular university and no public funding | Not found |
Status of main technology and facilities
| Technology / facility | Stage | Date | What the source says (company's description) |
|---|---|---|---|
| Clinical use of the LNP technology | Clinical trials | 31 March 2026 | Experience in "over a dozen distinct product candidates, representing thousands of subjects." Roivant and Genevant say the technology is in ONPATTRO, the first approved systemic RNA-LNP product (Arbutus also calls it the first approved product of its LNP technology) |
| Manufacturing process scale | Scaled up (company's statement) | Checked October 2026 | "Batch sizes of up to a kilogram of nucleic acid" to support future commercialization (website). The manufacturing site was not found |
| Next-generation ligand conjugates | Preclinical (non-human primates) | Checked October 2026 | Described as about an order of magnitude more potent than a standard GalNAc conjugate, with faster onset and longer duration (conditions and data are not in public materials) |
6. Track record
| When | Event | Meaning |
|---|---|---|
| 2018 | In April Roivant and Arbutus set up Genevant. Arbutus granted it an exclusive license to LNP and ligand conjugate technology outside hepatitis B and certain other fields (cross-license agreement of 11 April 2018, amended 27 June 2018) | Created as a vehicle to commercialize the technology |
| 2020-2021 | In July 2020 Roivant recapitalized the company under a shareholders agreement giving it substantial control; third amendment to the cross-license on 9 December 2021 | The control structure was fixed |
| 2022-2023 | Sued Moderna with Arbutus on 28 February 2022. Collaborations followed with Korro Bio (RNA editing, March 2023), Gritstone bio (option and license, August 2023) and Novo Nordisk (hemophilia A gene editing, November 2023, from an option exercised under a 2seventy bio agreement). Sued Pfizer/BioNTech on 4 April 2023 | Collaborations and litigation proceed in parallel |
| 2024 | Collaborations with Tome Biosciences (January), Repair Biotechnologies (September), Editas Medicine (October) and Epitopea (December). On 20 May Acuitas's declaratory judgment suit was dismissed without prejudice for lack of jurisdiction | Non-exclusive licenses accumulate |
| 2025 | In March the CEO and Executive Chair changed (Heyes, Lutwyche). On 3 March five international suits against Moderna (Roivant says 30 countries). On 9 September, the claim construction in the Pfizer case (which the company calls generally favorable) | International enforcement expands |
| 2026 | 3 March: settlement with Moderna ($950.0 million up front, $1.3 billion contingent). 19 March: suit against the United States. 30 June: the Pfizer case was administratively terminated (plaintiffs' letter). 8 July: received its $771.6 million share. July: three international suits against Pfizer/BioNTech | Its 2026 finances depend heavily on the settlement |
7. Plans
Oral argument expected 2027Roivant's 10-K (May 2026). The $1.3 billion payment depends on it
Canada and UPC: filed July 2026Per the plaintiffs' letter of 11 August 2026; the court's response was not found
to non-Roivant holdersExpected in Q3 2026 (Roivant's 10-Q)
"up to" amountsEditas up to $238 million; Epitopea up to $123.5 million per product; Repair up to $107 million per product. Receipt is not confirmed
Roivant says Genevant seeks "upfront payments, R&D reimbursements, milestones and royalties or profit sharing" from collaborations, while retaining certain rights in delivery-related intellectual property developed in them (company policy) Not yet confirmed. The public materials contain no plan for new collaborations or for products of its own.
None of the following appears in the primary sources Not yet confirmed.
Genevant's own revenue, profit and cash / the actual amount and timing of the parent's distribution / the trial date in the Pfizer/BioNTech case / plans for new collaborations / any plan to develop drugs itself / the manufacturing site / the development progress (trial stage) of each partner.
8. What the company is aiming for in nanotechnology
This section includes points the company does not state directly. They are written as inferences within what the primary sources allow, with their basis.
| What can be read | Primary-source basis | Type |
|---|---|---|
| It aims to be a provider of delivery technology that many companies can use | Roivant's 10-K: a technology-focused company focused on partnering. Website: collaborates "selectively" with leading pharma and biotech companies | Sourced (company policy) |
| The focus has shifted from the founding aim (developing nucleic acid and gene-editing therapeutics) to licensing technology and patents | Arbutus's 10-K: launched in 2018 as "a company focused on nucleic acid- and gene editing-based therapeutics enabled by our LNP and ligand conjugate delivery technologies." Roivant's 10-K: now focused on partnering | Inference |
| Collaborations are mainly non-exclusive licenses; it is not tied to a single partner | Press releases for Editas, Epitopea and Repair: all "nonexclusive worldwide" licenses | Inference |
| Settlement and litigation income accounts for most of its finances for now | Roivant's 10-K: a $770.2 million settlement gain against consolidated revenue of $8.26 million | Inference |
The basis for "the focus shifted from the founding aim to licensing" is the difference in wording between two documents describing the same company. Arbutus's 10-K describes the 2018 launch as that of a company "focused on nucleic acid- and gene editing-based therapeutics enabled by" LNP and ligand conjugate delivery. Roivant's 2026 10-K describes it today as a technology-focused nucleic acid delivery and development company "currently focused on partnering with other pharmaceutical or biotechnology companies."
However, no document was found in which Genevant itself says it has stopped developing therapeutics. The word "development" remains in Roivant's description, and it continues to develop delivery systems to fit partners' payloads. This is an inference from differences between documents, not the company's statement Not yet confirmed.
9. Partnership map for nanotechnology
The pattern is that the upstream (the licensor Arbutus, the parent Roivant) is close and the downstream (companies that use the technology) is broad. The four partners shown are all payload holders in gene editing or cancer immunotherapy, with Genevant supplying delivery. BioNTech's Form 20-F says it has licensed patent filings on lipid and lipid-nanoparticle formulations from Genevant as well as from Acuitas; yet Pfizer/BioNTech is also a defendant (the same 20-F says it has strong defenses). Sourced
10. Technologies, products and services
The following draws on the company's website, Roivant's 10-K and press releases. Performance statements are the company's own, and those without published test conditions cannot be used for comparison. Sourced
| Item | Content (company's description) |
|---|---|
| LNP platform | "500+ novel, in-house lipid compounds." Highlights biodegradable lipids (to reduce lipid accumulation without affecting potency), lyophilized drug product (to improve supply-chain efficiency) and delivery beyond the liver. Patents cover lipid structures (including cationic and PEG-lipids), particle compositions (ranges of lipid ratios), nucleic-acid particles with certain structural characteristics, mRNA-LNP formulations and manufacturing process aspects (Roivant) |
| Ligand conjugate platform | Multivalent GalNAc for hepatocytes and other structures for hepatic stellate cells, tumors and macrophages. Experience designing siRNA and chemical modifications. Endosomal entrapment is the main hurdle, and a next generation with endosomal release is in development |
| Payload design | Expertise in mRNA and siRNA payload design offered in collaborations |
| Collaboration terms (disclosed) | Editas: Cas12a mRNA-LNP products for two targets; up to $238 million (upfront and contingent milestones) plus tiered royalties. Epitopea: mRNA-LNP cancer immunotherapies; up to $123.5 million per product plus mid-to-high single-digit royalties. Repair: mRNA-LNP for atherosclerosis; up to $107 million per product plus similar royalties. All non-exclusive and worldwide |
| Rights granted to Moderna | A fully paid-up, irrevocable, non-exclusive, worldwide license for mRNA vaccines against infectious disease using an SM-102 lipid formulation (such as Spikevax) and a covenant not to sue on certain patents and products (March 2026 settlement), granted jointly with Arbutus |
| What the patents cover | The Pfizer case concerns five Arbutus patents (composition and manufacture of lipid nanoparticles). In September 2025 the court construed four terms (lipid vesicle, fully encapsulated, mol %, consisting essentially of); no ruling on infringement or validity has been made |
(1) The head-to-head claim has no published conditions. Roivant's 10-K says that in a mouse study of LNP formulations that varied only the key ionizable lipid, Genevant's formulation outperformed all third-party formulations tested, with superior potency and tolerability judged by immune stimulation. This is the company's claim. The names of the lipids compared, the doses, the endpoints and the number of animals are not in public materials, so no ranking against other formulations can be drawn from it, and mouse results need not carry over to humans.
(2) The four lipid types are common; the difference shows up in the molecular design of the ionizable lipid. The general makeup of LNPs (ionizable lipid, phospholipid, cholesterol, PEG-lipid) is shared across companies (see our explainer on lipid nanoparticles). The "biodegradable lipids" the company cites can therefore be read as a feature of the ionizable lipid's molecule (for example, introducing linkages that break down more readily). The company does not show molecular structures in public materials (our commentary).
(3) Lyophilization turns a logistics problem into a materials problem. The company cites a lyophilized product. Freeze-drying a liquid LNP tends to cause aggregation or leakage, so protective additives such as sugars generally have to be designed in. The composition and storage conditions of the company's product are not in public materials (our commentary).
(4) The patents split into an "older foundation" and "newer improvements." Genevant's own patents (29 families) expire 2029-2045, and those licensed from Arbutus (28 families, 485 issued) expire by 2041. The licensed block has many issued patents and Genevant's own block mostly pending applications (Roivant's 10-K; our calculation). One reading is that the older foundational patents near expiry while newer filings cover improvements, but the content of individual patents cannot be traced from public materials.
None of this judges whether the patents are valid or whether any actual product falls within their scope.
11. Risks
| Risk | Content | Type |
|---|---|---|
| Uncertainty of patent litigation | Roivant's 10-K says the Moderna resolution need not predict the Pfizer case and that even a district-court win can be overturned on appeal. BioNTech says it has strong defenses and the outcome is substantially uncertain. What the court issued in September 2025 was a claim construction, not a ruling on infringement or validity | Sourced |
| Challenges to patent validity | Patents were the subject of inter partes review proceedings brought by Moderna, whose decisions were reviewed by the Federal Circuit (Roivant's 10-K). The EPO Board of Appeal revoked EP 2279254 in an oral decision in January 2026 (Arbutus's 10-K) | Sourced |
| The contingent $1.3 billion | Conditional on a favorable ruling in Moderna's §1498 appeal; prorated if only some doses are covered and nil if all are. If later overturned it must be returned with interest. Roivant says a repayment obligation arising after proceeds are deployed or distributed could materially affect its consolidated finances | Sourced |
| Expiry of licensed patents | Patents licensed from Arbutus have already begun to expire (Roivant's text gives both "as early as 2023" and "June 2025 to 2041" in different places). Royalties on licensed products run until the last valid claim expires in each country | Sourced |
| Reliance on Roivant and Arbutus | Genevant's core patents are licensed from Arbutus, and sublicensing and litigation income is shared with it. Roivant controls management. Stand-alone financials are not disclosed, so soundness cannot be assessed from outside | Sourced |
| Partners' business risk | Partnership income depends on partners' development success. For example, per Arbutus's 10-K, Gritstone filed for Chapter 11 in October 2024 and its assets were bought by Seattle Project Corp. The amounts are "up to" figures, and receipt is not confirmed | Sourced |
| Competition from other delivery technologies | Others, such as Acuitas, provide different LNP technology (BioNTech also licenses from Acuitas). Non-exclusive licenses mean partners can use more than one technology | Inference |
| Use and distribution of proceeds | Of the $771.6 million received, up to $188 million is to be distributed, and there are litigation costs and bonuses; the treatment of the remainder is not disclosed | Not yet confirmed |
12. Glossary
- LNP (lipid nanoparticle)
- A particle of lipids that encloses and carries nucleic acids (mRNA, siRNA). See our explainer on lipid nanoparticles.
- Ligand conjugate
- A delivery format in which a molecule that binds a receptor on the target cell (a ligand) is attached directly to the nucleic acid. GalNAc targets liver cells.
- Payload
- The cargo being delivered (mRNA, siRNA, gene-editing components and so on).
- Extrahepatic delivery
- LNPs given intravenously tend to accumulate in the liver; this means reaching other organs and cells.
- Non-exclusive license
- A license under which the same technology may also be licensed to others.
- Milestone
- A contractual payment made when development or sales reach a defined stage.
- Cross-license
- An agreement in which the parties license rights to each other, as between Genevant and Arbutus.
- 28 U.S.C. §1498
- A US statute under which, when a patented invention is used for the US government, the patent owner seeks compensation from the government; Moderna raised it as a defense.
- Lyophilization
- Freezing and sublimating water to make a powder, which limits changes during storage.
13. References
- Roivant Sciences Annual Report on Form 10-K for the year ended 31 March 2026 (filed 20 May 2026). Genevant overview, cross-license with Arbutus, patent counts and expiry, litigation, accounting for the settlement, ownership. https://www.sec.gov/Archives/edgar/data/1635088/000163508826000061/roiv-20260331.htm
- Roivant Sciences Quarterly Report on Form 10-Q for the quarter ended 30 June 2026 (filed 6 August 2026). Amount of the settlement payment received, expected distribution by the parent, bonus accrual. https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm
- Roivant Sciences Form 8-K (filed 3 March 2026). Terms of the settlement agreement with Moderna. https://www.sec.gov/Archives/edgar/data/1635088/000114036126007548/ef20067067_8k.htm
- Arbutus Biopharma Annual Report on Form 10-K for the year ended 31 December 2025 (filed 23 March 2026). Formation of Genevant and license terms, about 16% equity, litigation, estimated patent expiry. https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/abus-20251231.htm
- Arbutus Biopharma Quarterly Report on Form 10-Q for the quarter ended 30 June 2026 (filed 12 August 2026). License revenue from Genevant, receipt of the settlement payment, new lawsuits. https://www.sec.gov/Archives/edgar/data/1447028/000144702826000045/abus-20260630.htm
- Arbutus Biopharma Form 8-K (filed 3 March 2026). Settlement agreement with Moderna (Genevant a joint party). https://www.sec.gov/Archives/edgar/data/1447028/000117184326001299/f8k_030326.htm
- U.S. District Court for the District of New Jersey Arbutus Pharma Corp. v. Pfizer Inc., No. 3:23-cv-1876, ECF 246, Claim Construction Opinion (9 September 2025). https://storage.courtlistener.com/recap/gov.uscourts.njd.510890/gov.uscourts.njd.510890.246.0.pdf
- U.S. District Court for the District of New Jersey (plaintiffs' letter) Same case, ECF 324 (11 August 2026). Letter from the plaintiffs' (Arbutus and Genevant) counsel on the 30 June 2026 administrative termination and requests to reopen and set a schedule. Contains plaintiffs' own positions. https://storage.courtlistener.com/recap/gov.uscourts.njd.510890/gov.uscourts.njd.510890.324.0.pdf
- U.S. District Court for the District of New Jersey Acuitas Therapeutics Inc. v. Genevant Sciences GmbH, No. 3:23-cv-4200, ECF 35, Opinion (20 May 2024). https://storage.courtlistener.com/recap/gov.uscourts.njd.515917/gov.uscourts.njd.515917.35.0_1.pdf
- BioNTech Annual Report on Form 20-F for the year ended 31 December 2025 (filed 10 March 2026). Defendant's description (strong defenses, uncertain outcome) and mention of licenses from Genevant. https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/bntx-20251231.htm
- Genevant Sciences Official website, "About us". Company description, patent, lipid-compound and clinical-program counts as stated by the company. https://www.genevant.com/about-us/
- Genevant Sciences Official website, "Our technology". The LNP and ligand conjugate platforms, biodegradable lipids, lyophilized drug product, extrahepatic delivery, manufacturing scale. https://www.genevant.com/our-technology/
- Genevant Sciences Official website, "Contact us". Locations (Vancouver, Cambridge, Basel). https://www.genevant.com/contact-us/
- Genevant Sciences Official website, "Our management". Management (CEO and Executive Chair changed in March 2025). https://www.genevant.com/team/
- Genevant Sciences Official website news list. Announcements of collaborations and enforcement actions, 2023-2026. https://www.genevant.com/news/
- Genevant Sciences and Arbutus Biopharma Press release (3 March 2026). Announcement of the settlement with Moderna. https://www.genevant.com/genevant-sciences-and-arbutus-biopharma-announce-2-25-billion-global-settlement-with-moderna/
- Genevant Sciences and Arbutus Biopharma Press release (3 March 2025). Filing of five international suits against Moderna. https://www.genevant.com/genevant-sciences-and-arbutus-biopharma-initiate-international-patent-infringement-enforcement-actions-against-moderna/
- Editas Medicine and Genevant Sciences Press release (21 October 2024). Non-exclusive license and collaboration; up to $238 million in upfront and contingent milestones. https://www.genevant.com/editas-medicine-and-genevant-sciences-to-collaborate-to-develop-novel-mrna-lnp-gene-editing-therapeutics/
- Epitopea and Genevant Sciences Press release (19 December 2024). Non-exclusive license; up to $123.5 million per product. https://www.genevant.com/epitopea-and-genevant-sciences-announce-collaboration-agreement/
- Repair Biotechnologies and Genevant Sciences Press release (26 September 2024). Non-exclusive license; up to $107 million per product. https://www.genevant.com/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis/
- Genevant Sciences Press release (6 November 2023). Collaboration with Novo Nordisk on gene editing for hemophilia A (arising from the exercise of an option under an agreement with 2seventy bio). https://www.genevant.com/genevant-sciences-to-collaborate-with-novo-nordisk-to-develop-gene-editing-treatment-for-hemophilia-a/
14. Claim-to-source audit
| Claim in the text | Type | Source |
|---|---|---|
| Genevant's nature: a technology-focused nucleic acid delivery and development company focused on partnering (Roivant's description); two platforms (LNP and ligand conjugates); revenue model (upfront, R&D reimbursement, milestones, royalties or profit sharing) | Sourced (company's claim) | References 1, 11, 12 https://www.sec.gov/Archives/edgar/data/1635088/000163508826000061/roiv-20260331.htm https://www.genevant.com/about-us/ https://www.genevant.com/our-technology/ |
| Ownership (Roivant 83%, 64% fully diluted; Arbutus about 16%), the April 2018 formation, the July 2020 recapitalization, Roivant's substantial control, Arbutus's non-voting observer | Sourced | References 1, 4, 2 https://www.sec.gov/Archives/edgar/data/1635088/000163508826000061/roiv-20260331.htm https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/abus-20251231.htm https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm |
| Cross-license terms: exclusive, worldwide, sublicensable, outside hepatitis B and certain fields; 20% (14% for a collaboration) of sublicensing income; 20% of litigation proceeds or low single-digit royalties; agreements and amendments of 11 April 2018, 27 June 2018 and 9 December 2021 | Sourced | References 1, 4 https://www.sec.gov/Archives/edgar/data/1635088/000163508826000061/roiv-20260331.htm https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/abus-20251231.htm |
| Patent counts and expiry: own 29 families (45 issued, 118 pending, 2029-2045), licensed from Arbutus 28 families (485 issued, 110 pending, June 2025-2041), "more than 700" | Sourced (company's claim) | References 1, 11 https://www.sec.gov/Archives/edgar/data/1635088/000163508826000061/roiv-20260331.htm https://www.genevant.com/about-us/ |
| The 3 March 2026 settlement with Moderna: $950.0 million up front (paid 8 July 2026), $1.3 billion contingent, the §1498 appeal, license scope, consent to judgments, the 80%/20% split | Sourced | References 3, 1, 2, 6, 16 https://www.sec.gov/Archives/edgar/data/1635088/000114036126007548/ef20067067_8k.htm https://www.sec.gov/Archives/edgar/data/1635088/000163508826000061/roiv-20260331.htm https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm https://www.sec.gov/Archives/edgar/data/1447028/000117184326001299/f8k_030326.htm https://www.genevant.com/genevant-sciences-and-arbutus-biopharma-announce-2-25-billion-global-settlement-with-moderna/ |
| Genevant's $771.6 million received on 8 July, the $770.2 million settlement gain for the year to March 2026, Roivant's consolidated revenue of $8.26 million (mainly Genevant licenses), the $22.9 million bonus accrual, the expected distribution of up to $188 million | Sourced | References 1, 2 https://www.sec.gov/Archives/edgar/data/1635088/000163508826000061/roiv-20260331.htm https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm |
| Arbutus's side: receipt of its $178.4 million share, license revenue from Genevant of $179,373 thousand, termination of the RSV agreement | Sourced | References 5, 4 https://www.sec.gov/Archives/edgar/data/1447028/000144702826000045/abus-20260630.htm https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/abus-20251231.htm |
| Moderna's §1498 appeal (notice March 2026; oral argument expected 2027), the five international suits of March 2025 (30 countries), the three international suits against Pfizer/BioNTech in July 2026 | Sourced | References 1, 17, 5 https://www.sec.gov/Archives/edgar/data/1635088/000163508826000061/roiv-20260331.htm https://www.genevant.com/genevant-sciences-and-arbutus-biopharma-initiate-international-patent-infringement-enforcement-actions-against-moderna/ https://www.sec.gov/Archives/edgar/data/1447028/000144702826000045/abus-20260630.htm |
| The Pfizer case: filed April 2023, five patents, claim construction (9 September 2025, four terms), the 30 June 2026 administrative termination and plaintiffs' request to reopen (plaintiffs' position) | Sourced | References 7, 8, 1 https://storage.courtlistener.com/recap/gov.uscourts.njd.510890/gov.uscourts.njd.510890.246.0.pdf https://storage.courtlistener.com/recap/gov.uscourts.njd.510890/gov.uscourts.njd.510890.324.0.pdf https://www.sec.gov/Archives/edgar/data/1635088/000163508826000061/roiv-20260331.htm |
| BioNTech's view (strong defenses, outcome substantially uncertain) and its licenses from Acuitas and Genevant | Sourced | Reference 10 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/bntx-20251231.htm |
| Dismissal of Acuitas's declaratory judgment suit (20 May 2024; lack of jurisdiction; without prejudice) | Sourced | Reference 9 https://storage.courtlistener.com/recap/gov.uscourts.njd.515917/gov.uscourts.njd.515917.35.0_1.pdf |
| Collaboration terms: Editas (21 October 2024; up to $238 million), Epitopea (19 December 2024; up to $123.5 million per product), Repair (26 September 2024; up to $107 million per product), Novo Nordisk (6 November 2023), all non-exclusive | Sourced | References 18, 19, 20, 21 https://www.genevant.com/editas-medicine-and-genevant-sciences-to-collaborate-to-develop-novel-mrna-lnp-gene-editing-therapeutics/ https://www.genevant.com/epitopea-and-genevant-sciences-announce-collaboration-agreement/ https://www.genevant.com/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis/ https://www.genevant.com/genevant-sciences-to-collaborate-with-novo-nordisk-to-develop-gene-editing-treatment-for-hemophilia-a/ |
| Announcements with Korro Bio (March 2023), Gritstone bio (August 2023) and Tome Biosciences (January 2024), and Mammoth Biotechnologies among current partners | Sourced | References 15, 1 https://www.genevant.com/news/ https://www.sec.gov/Archives/edgar/data/1635088/000163508826000061/roiv-20260331.htm |
| Locations (Vancouver, Cambridge, Basel) and management (CEO and Executive Chair changed in March 2025) | Sourced | References 13, 14 https://www.genevant.com/contact-us/ https://www.genevant.com/team/ |
| Technology features (biodegradable lipids, lyophilized product, extrahepatic delivery, 500+ in-house lipids, batches up to 1 kg of nucleic acid, potency of the next-generation ligand conjugate) | Sourced (company's claim) | References 12, 11 https://www.genevant.com/our-technology/ https://www.genevant.com/about-us/ |
| The mouse head-to-head claim (formulations varying only the ionizable lipid outperformed third-party formulations) and clinical experience in over a dozen candidates | Sourced (company's claim) | References 1, 11 https://www.sec.gov/Archives/edgar/data/1635088/000163508826000061/roiv-20260331.htm https://www.genevant.com/about-us/ |
| Gritstone's Chapter 11 filing (October 2024) and sale of assets to Seattle Project Corp. (Arbutus's 10-K) | Sourced | Reference 4 https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/abus-20251231.htm |
| The logo image is the corporate logo published in the header of the official website | Sourced | Reference 11 https://www.genevant.com/about-us/ |
| Genevant's own revenue, profit and headcount, R&D and capex, universities and public funding, manufacturing site, the actual amount and timing of the parent's distribution, trial date and plans for new collaborations | Not yet confirmed | Not in official materials; this article does not assert they do not exist (this article) |
| The readings "the focus shifted from developing therapeutics to licensing," "non-exclusive licenses are the core" and "settlement income is most of its finances for now" | Inference | References 4, 1, 18, 19, 20 https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/abus-20251231.htm https://www.sec.gov/Archives/edgar/data/1635088/000163508826000061/roiv-20260331.htm https://www.genevant.com/editas-medicine-and-genevant-sciences-to-collaborate-to-develop-novel-mrna-lnp-gene-editing-therapeutics/ https://www.genevant.com/epitopea-and-genevant-sciences-announce-collaboration-agreement/ https://www.genevant.com/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis/ |
| Classifying Genevant as "nanomedicine," the four-type scheme, the 758-patent total (45 + 118 + 485 + 110) and the commentary in the materials-engineer section | Our calculation | Our own organization and calculation (see our technical explainers for general technology background) |
Last updated: 9 October 2026 / Troy Technical
This article is based on Roivant's Forms 10-K, 10-Q and 8-K, Arbutus's Forms 10-K, 10-Q and 8-K, Genevant's website and press releases, District of New Jersey court documents and BioNTech's Form 20-F. It uses no market-research estimates or press-based figures. Because Genevant is not listed, its own financials are not published, and this article does not estimate them. Partnership amounts are "up to" figures and do not indicate receipt. Patent litigation is treated as each party's position, and this article does not judge whether any patent is valid or infringed. Items marked "Inference" are our reading of the primary sources and are not company disclosures. This article does not advise individual readers on the efficacy or safety of any medicine, or on investment.